John H. Leaman - 31 Dec 2022 Form 4 Insider Report for IMPEL PHARMACEUTICALS INC

Role: Chief Fin. & Business Officer
Signature: /s/ John Leaman, M.D.
Issuer symbol: N/A
Transactions as of: 31 Dec 2022
Net transactions value: -$13,601
Form type: 4
Filing time: 04 Jan 2023, 17:46:05 UTC
Previous filing: 28 Jan 2022
Next filing: 16 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMPL	Common Stock	Options Exercise	$0	+10,571		$0.000000	10,571	31 Dec 2022	Direct
transaction	IMPL	Common Stock	Tax liability	$13,601	-3,627	-34%	$3.75	6,944	31 Dec 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMPL	Restricted Stock Units (RSUs)	Options Exercise	$0	-10,571	-100%	$0.000000^*	0	31 Dec 2022	Common Stock	10,571		Direct	F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the restricted stock units ("RSUs") and does not represent a sale by the reporting person.
F2	Each RSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement.
F3	The RSUs vest as to 100% of the total shares on December 31, 2022, subject to the Reporting Person's continuation of employment on such vesting date.
F4	RSUs do not expire; they either vest or are canceled prior to the vesting date.